Measuring disease specific quality of life in localized prostate cancer: The Dutch experience

Quality of Life Research

Volumn 12, Issue 4, 2003, Pages 459-464

  Korfage, I J ^a   Essink Bot, M L ^a   Madalinska, J B ^a   Kirkels, W J ^a   Litwin, M S ^b   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cross cultural adaptation; Health status; Impotence; Prostactic neoplasmus; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; ERECTILE DYSFUNCTION; HUMAN; INTESTINE FUNCTION; KIDNEY FUNCTION; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NETHERLANDS; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PSYCHOMETRY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RELIABILITY; SCALE UP; SCORING SYSTEM; SEXUAL BEHAVIOR; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VALIDATION PROCESS;

AGED; HUMANS; IMPOTENCE; MALE; NETHERLANDS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 0038287899     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023402706666     Document Type: Article

References (12)

1. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19(6): 1619-1628.
2. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001; 46(2): 87-97.
3. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97(2): 237-244.
4. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: A response. Qual Life Res 2001; 10(5): 405-413; discussion 415-420.
5. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-1108.
6. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36(7): 1002-1012.
7. Slob AK, Blom JH, van der Werff ten Bosch JJ. Erection problems in medical practice: Differential diagnosis with relatively simple method. J Urol 1990; 143(1): 46-50.
8. Incrocci L, Madalinska JB, Essink-Bot ML, Van Putten WL, Koper PC, Schroder FH. Sexual functioning in patients with localized prostate cancer awaiting treatment. J Sex Marital Ther 2001; 27(4): 353-363.
9. Staquet MJ, Hays RD, Fayers PM. Quality of Life Assessment in Clinical Trials, Methods and Practice. Oxford University Press, 1998.
10. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1977.
11. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822-830.
12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56(6): 899-905.